T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
作者： Z. Wu , N.V. Cheung
DOI: 10.1016/J.PHARMTHERA.2017.08.005
关键词:
摘要: Harnessing the power of human immune system to treat cancer is essence immunotherapy. Monoclonal antibodies engage innate destroy targeted cells. For last 30years, antibody-dependent cell-mediated cytotoxicity and complement-dependent have been main mechanisms anti-tumor action unconjugated antibody drugs. Efforts exploit potentials other cells, in particular T culminated recent approval two cell engaging bispecific (T-BsAb) drugs, thereby stimulating new efforts accelerate similar platforms through preclinical clinical trials. In this review, we compiled worldwide effort exploring antibodies. Our special emphasis on lessons learned, with hope derive insights fast evolving field tremendous potential.
elsevier.com
sci-hub.se 参考文章(198)
Peter T. Daniel, Arne Kroidl, Joachim Kopp, Isrid Sturm, Gerhard Moldenhauer, Bernd Dörken, Antonio Pezzutto, Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells Blood. ,vol. 92, pp. 4750- 4757 ,(1998) , 10.1182/BLOOD.V92.12.4750
Ling Huang, Leslie S. Johnson, Cd3-binding molecules capable of binding to human and non-human cd3 ,(2012)
Christopher H. Contag, Yolanda C. Scheffold, Robert S. Negrin, Martin Kornacker, Christian Scheffold, Visualization of Effective Tumor Targeting by CD8+ Natural Killer T Cells Redirected with Bispecific Antibody F(ab′)2HER2xCD3 Cancer Research. ,vol. 62, pp. 5785- 5791 ,(2002)
Sarita Chaubal, Stephan Lang, Bärbel Schmitt, Reinhard Zeidler, Horst Lindhofer, Gilbert Reisbach, Barbara Wollenberg, Simultaneous Activation of T Cells and Accessory Cells by a New Class of Intact Bispecific Antibody Results in Efficient Tumor Cell Killing Journal of Immunology. ,vol. 163, pp. 1246- 1252 ,(1999)
Delia Mezzanzanica, Donald S. Neblock, John R. Wunderlich, David M. Segal, Vincent R. Zurawski, Maria A. Garrido, Peter E. Daddona, Sarah M. Andrew, Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab')2 antibody prolong host survival in a murine xenograft model. Cancer Research. ,vol. 51, pp. 5716- 5721 ,(1991)
Paul A. Moore, Ralph Alderson, Kalpana Shah, Yinhua Yang, Steve Burke, Hua Li, Valentine Ciccarone, Ezio Bonvini, Syd Johnson, Abstract 669: Development of MGD007, a gpA33 x CD3 bi-specific DART for T-cell immunotherapy of metastatic colorectal cancer Cancer Research. ,vol. 74, pp. 669- 669 ,(2014) , 10.1158/1538-7445.AM2014-669
Torsten Dreier, Patrick A. Baeuerle, Iduna Fichtner, Michael Grün, Bernd Schlereth, Grit Lorenczewski, Peter Kufer, Ralf Lutterbüse, Gert Riethmüller, Per Gjorstrup, Ralf C. Bargou, T Cell Costimulus-Independent and Very Efficacious Inhibition of Tumor Growth in Mice Bearing Subcutaneous or Leukemic Human B Cell Lymphoma Xenografts by a CD19-/CD3- Bispecific Single-Chain Antibody Construct Journal of Immunology. ,vol. 170, pp. 4397- 4402 ,(2003) , 10.4049/JIMMUNOL.170.8.4397
Xiufeng Wu, Arlene J Sereno, Flora Huang, Steven M Lewis, Ricky L Lieu, Caroline Weldon, Carina Torres, Cody Fine, Micheal A Batt, Jonathan R Fitchett, Andrew L Glasebrook, Brian Kuhlman, Stephen J Demarest, Fab-based bispecific antibody formats with robust biophysical properties and biological activity. mAbs. ,vol. 7, pp. 470- 482 ,(2015) , 10.1080/19420862.2015.1022694
Birgit Kohleisen, Patrick Bäuerle, Steven Zeman, Ralf Lutterbüse, Peter Kufer, Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders ,(2004)
Ellen S. Vitetta, Guo Liang Shen, Jia Ling Li, Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing. Journal of Immunology. ,vol. 152, pp. 2368- 2376 ,(1994)